Table 3.
Baseline Demographic and Clinical Characteristics of Patients by the Composite Outcome After Multiple Imputation
| Composite Outcome (n = 42) | No Composite Outcome (n = 196) | P Value | |
|---|---|---|---|
| Age, ya | 63.6 (55.6–72.4) | 62.2 (53.3–70.8) | .18 |
| Male | 25 (59.5) | 25 (59.5) | .32 |
| White | 30 (71.4) | 149 (76.0) | .54 |
| Hispanic | 2 (4.8) | 12 (6.1) | .91 |
| Type of immunosuppression | .58 | ||
| Solid organ transplant | 16 (38.1) | 60 (30.6) | |
| Bone marrow transplant | 3 (7.1) | 21 (10.7) | |
| Leukemia/lymphoma | 8 (19.0) | 40 (20.4) | |
| Solid tumor | 7 (16.7) | 37 (18.9) | |
| Immunomodulator | 8 (19.0) | 38 (19.4) | |
| CCIa | 6 (3.5–8) | 5 (3–8) | .44 |
| Dialysis | 5 (11.9) | 18 (9.2) | .59 |
| CDI in past 6 mo | 1 (2.4) | 3 (1.5) | .57 |
| Any history of CDI | 5 (11.9) | 24 (12.2) | .94 |
| Gastric acid suppression | 27 (64.3) | 114 (58.2) | .46 |
| Location prior to diagnosis | .92 | ||
| Hospital acquired | 17 (40.5) | 86 (43.9) | |
| Health care associated | 14 (33.3) | 56 (28.6) | |
| Community acquired | 11 (26.2) | 55 (28.1) | |
| CDI test type | .05 | ||
| Toxin and antigen assay | 30 (71.4) | 106 (54.1) | |
| NAAT (toxin gene) | 12 (28.6) | 90 (45.9) | |
| Severe CDI | 18 (42.9) | 74 (37.8) | .63 |
| ICU stay | 11 (26.2) | 33 (16.8) | .17 |
| Antecedent antibiotic use | 37 (88.1) | 139 (70.9) | .034 |
| No. of antecedent antibioticsa | 2 (1–3) | 1 (0–2) | .011 |
| Antibiotics during treatment | 23 (54.8) | 100 (51.0) | .66 |
Data are presented as median (IQR) or No. (%). Chi-square was used for all testing unless otherwise specified.
Abbreviations: CCI, Charlson Comorbidity Index; CDI, Clostridioides difficile infection; ICU, intensive care unit.
aMann-Whitney U test.